1. Introduction {#sec1}
===============

Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver and accounts for as many as 1 million deaths annually worldwide \[[@B4]--[@B3]\]. The major risk factors include chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, environmental carcinogens such as aflatoxin B1 (AFB1), alcoholic cirrhosis, and inherited genetic disorder such as hemochromatosis, Wilson disease, and tyrosinemia. Among them, HBV, HCV, and AFB1 are responsible for approximately 80% of all HCC \[[@B4], [@B5]\]. Research on molecular genetics and pathogenesis of HCC has become a hot spot in cancer study because of its scientific merits and its clinical importance. Despite rapid expansion of information obtained from these researchers, the molecular mechanism of hepatocarcinogenesis and molecular genetics of HCC remain elusive.

The Wnt/*β*-catenin signaling pathway plays an important role in liver physiology and pathology by regulating a variety of crucial cellular events, including differentiation, proliferation, and survival \[[@B7]--[@B8]\]. The Wnt/*β*-catenin pathway can be activated through mutations in *CTNNB1* (encoding *β*-catenin), *AXIN1*, and *AXIN2* \[[@B7], [@B9]\] in human HCC. The common event is the stabilization of *β*-catenin, which translocates into the nucleus and associates with the T-cell factor (TCF) family of transcription factors for efficient activation of Wnt target genes \[[@B10]--[@B17]\]. In addition to genetic mutations, epigenetic changes are also involved in the aberrant activation of Wnt/*β*-catenin signaling pathway in cancer cells \[[@B7], [@B9], [@B21]--[@B22]\].

Abnormal hypermethylation of CpG islands serves as another mechanism for inactivation of the tumor suppressor gene (TSG) in cancer \[[@B23]--[@B25]\]. Hypermethylation of gene promoters has been demonstrated as an early event in hepatocellular carcinogenesis \[[@B26]--[@B28]\]. The secreted frizzled-related proteins (SFRPs) function as negative regulators of Wnt signaling and have important implications for carcinogenesis \[[@B29]\]. The secreted frizzled-related protein (SFRP) family plays a significant role in the inhibition of the Wnt signaling pathway in various cancers \[[@B30]\]. The frizzled-related protein (SFRP3) is generally thought to be an inhibitor of Wnt signaling in several cancers \[[@B31], [@B32]\]. Some reports have demonstrated that SFRP3 has tumor-suppressing activities and could inhibit cell invasiveness in prostate cancer and melanoma cells \[[@B31], [@B32]\]. However, SFRP3 promotes cell growth, invasion, and inhibition of apoptosis in renal cancer cells \[[@B33]\]. Because there have been no reports about the role of *SFRP3* in hepatocellular carcinoma (HCC), we investigated the level of methylation and transcription of *SFRP3*.

Recently, we have shown that*SFRPs* are often downregulated through promoter hypermethylation in HCC cell lines and clinical HCC tissues \[[@B21], [@B34]\]. Furthermore, we have demonstrated that restoration of *SFRPs*could attenuate Wnt signaling in HCC cells with *β*-catenin mutation, decrease aberrant accumulation of free *β*-catenin in the nucleus, and then suppress cell growth \[[@B34]\]. We hypothesized that CpG island methylation of the *SFRP3* promoter may play an important role in regulating *SFRP3*expression in HCC. To test this hypothesis, we used MS-PCR, QMSP, and bisulfite sequencing method to analyze the*SFRP3* methylation pattern in HCCs. The mRNA expression was assessed by quantitative RT-PCR assay. Further, we determined whether treatment of HCC cell lines with a DNA methylation inhibitor, 5-aza-2′-deoxycytidine (5-Aza-CdR), could then restore or increase expression of the *SFRP3*mRNA.

2. Materials and Methods {#sec2}
========================

2.1. Tissue Specimens {#sec2.1}
---------------------

Sixty paired HCC samples (including HCC tissues, DNA, and RNA samples) and 30 hepatic hemangioma tissues were provided by the Taiwan Liver Cancer Network (TLCN). The TLCN is funded by the National Science Council to provide researchers in Taiwan with primary liver cancer tissues and their associated clinical information. The diagnosis of HCC was confirmed by histology. Experienced pathologist classified the nontumor tissues as chronic hepatitis livers (23 cases) and cirrhosis livers (37 cases). The use of the 60 HCC tissues, paired nontumor parts, and 30 hepatic hemangioma tissues (as control livers) in this study was approved by the Institutional Review Board and the TLCN User Committee.

2.2. Cell Lines {#sec2.2}
---------------

We obtained three human HCC cell lines from the American Type Culture Collection (ATCC, Rockville, MD): HepG2, HA22T, Hep3B, and TONG. They were all grown in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 10% (w/v) fetal bovine serum, penicillin at 100 U/mL, streptomycin at 100 *μ*g/mL, and L-glutamine at 2 mmol/L (all from Invitrogen, Carlsbad, CA) at 37°C in an atmosphere of 5% (v/v) CO~2~ in air.

2.3. 5-Aza-2′-deoxycytidine Treatment {#sec2.3}
-------------------------------------

HCC cells were seeded at a density of 1 × 10^5^ cells/100-millimeter dish and allowed to attach for 24 hr. Cells were incubated in 5 µM 5-aza-2′-deoxycytidine (5-Aza-CdR; Sigma Chemical Co., St. Louis, MO) diluted in phosphate-buffered saline (PBS) or in PBS alone for 96 hr to analyze the effect of methylation inhibition on *SFRP3* mRNA expression. All incubations were performed in duplicate dishes, and cells were harvested directly for RNA and DNA isolation.

2.4. DNA Extraction {#sec2.4}
-------------------

Genomic DNA was extracted from cell lines and tissue samples using a commercial DNA extraction kit (QIAmp Tissue Kit; Qiagen, Hilden, Germany). DNA was isolated according to the manufacturer\'s protocol.

2.5. Bisulfite Modification and Methylation-Specific PCR (MS-PCR) {#sec2.5}
-----------------------------------------------------------------

Genomic DNA isolated from cells and tissue was subjected to bisulfite methylation analysis. We treated DNA with bisulfite using an EZ DNA methylation kit (Zymo Research, Orange, CA) according to the protocol described in the user manual. Briefly, one µg of genomic DNA was denatured by incubation with 0.2 M NaOH. Aliquots of 10 mM hydroquinone and 3 M sodium bisulfite (pH 5.0) were added and the solution was incubated at 50°C for 16 hr. Treated DNA was purified on a Zymo-Spin I column, desulfonated with 0.3 M NaOH, repurified on a Zymo-Spin I column, and resuspended in 20 *μ*L elution buffer. MS-PCR \[[@B35]\] was carried out in a volume of 25 *μ*L containing 1 *μ*L of the sodium-bisulfite-treated DNA with Gold *Taq* DNA polymerase (PE Applied Biosystems, Foster City, CA) as follows. After heating at 92°C for 10 min, PCR was performed in a thermal cycler (GeneAmp 2400, PE Applied Biosystems) for 35 cycles, each of which consisted of denaturation at 92°C for 30 sec, annealing at 61°C for 30 sec, and extension at 72°C for 30 sec, followed by a final 10 min extension at 72°C. The PCR products were analyzed by electrophoresis on a 3% agarose gel. The experiments were repeated three times to ensure reproducibility. The sequences of *SFRP3* promoter, primer, and probes are summarized in [Table 1](#tab1){ref-type="table"}.

2.6. Bisulfite Sequencing {#sec2.6}
-------------------------

Bisulfite-treated genomic DNA was amplified using specific primers for human *SFRP3.* Amplified PCR product was purified and cloned into pCR4-TOPO vector (Invitrogen, Carlsbad, CA). DNA sequencing was performed on at least 5 individual clones using the 377 automatic sequencer (Applied Biosystems, Foster City, CA, USA). The primer sequences and the locations are summarized in [Table 1](#tab1){ref-type="table"}.

2.7. Quantitative Methylation-Specific PCR (QMSP) {#sec2.7}
-------------------------------------------------

TagMan-based QMSP (MethyLight) \[[@B36]\] method was used to determine the methylation level of HCCs. We used type II collagen gene (*COL2A*) for an internal reference gene by amplifying the non-CpG sequences. Each sample was analyzed three times. The genomic DNA treatment with M.Sss I methyltransferase (New England Biolabs, Beverly, MA) was used as positive control. The QMSP reactions were done as our previous report \[[@B37]\]. The relative DNA methylation was determined based on the threshold cycles (Ct) of the gene of interest and of the internal reference gene (*COL2A*). The relative DNA methylation level \[sample_gene/sample\_*COL2A*\] was calculated by the ΔCt method \[[@B36], [@B38]\]. Testing results with Ct-value of *COL2A* greater than 40 were determined as detection failure.

2.8. Quantitative RT-PCR {#sec2.8}
------------------------

Quantitative RT-PCR analysis was performed on an ABI PRISM 7700 Sequence Detector (Applied Biosystems, Forster City, USA). The match primers and TagMan Probe were obtained from commercial Applied Biosystems Tagman Assay-on Demand Gene Expression products. Glyceraldehyde-3-phosphate dehydrogenase gene (*GAPDH*) was used as an internal control. PCR reaction was carried out using TaqMan PCR master mix reagents kit. Relative gene expression was determined based on the threshold cycles (Ct) of the gene of interest and of the internal reference gene. The mRNA levels of the interest genes were expressed as the ratio of the interest gene to *GAPDH* mRNA for each sample. The level of each interest gene mRNA in each cancer was compared to the level in the corresponding nontumor part \[[@B39]\]. The average Ct value of the *GAPDH*gene was subtracted from the average Ct value of the interest genes for each sample: SFRP3 ΔCt = (Avg. SFRP3 Ct − Avg. GAPDH Ct) and SFRP3 ΔΔCt = (Avg. SFRP3  ΔCt~tumor~ − Avg.  SFRP3  ΔCt~nontumor~). The fold change (2^−SFRP3ΔΔCt^) in expression of the target genes (*SFRP3*) relative to the internal control gene (*GAPDH*) of each analyzed HCC sample was calculated \[[@B21], [@B39]\].

2.9. Statistical Analysis {#sec2.9}
-------------------------

Associations between methylation of *SFRP3*and clinical parameters were analyzed by using a chi-square test and Fisher\'s exact test, where necessary. We correlated the *SFRP3*methylation status with the liver disease status (control, chronic hepatitis, cirrhosis liver, and HCC) and downregulation of *SFRP3* mRNA expression. Significant differences were analyzed using the paired sample *t*-test or Mann-Whitney *U* test. The significance level was defined as *P* value \< 0.05.

3. Results {#sec3}
==========

3.1. Hypermethylation of *SFRP3*Promoter in Primary HCCs {#sec3.1}
--------------------------------------------------------

To investigate the promoter methylation of *SFRP3* in HCC, we first tested for promoter methylation in 30 control livers, 60 primary HCCs, and their corresponding nontumor tissues using MSP (Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}, [Table 2](#tab2){ref-type="table"}). Aberrant promoter methylation of*SFRP3* gene was observed in 60%, 39.1%, 16.2%, and 0% in primary HCCs, cirrhosis livers, chronic hepatitis livers, and normal controls, respectively. The methylation level within the *SFRP3* promoter was then validated by bisulfite sequencing. Representative results for bisulfite sequencing are shown in [Figure 1(c)](#fig1){ref-type="fig"}. The CpGs in these regions were frequently methylated in HCC tumors ([Figure 1(c)](#fig1){ref-type="fig"}, 5T). The methylation of *SFRP3*promoter was detected in some nontumor parts from HCC patients with chronic hepatitis or cirrhosis ([Figure 1(c)](#fig1){ref-type="fig"}, 5NT). In contrast, we did not detect promoter hypermethylation in control liver tissues ([Figure 1(c)](#fig1){ref-type="fig"}, N4). Our data showed that methylation level of*SFRP3*promoter region in HCCs increased significantly compared with control livers ([Table 3](#tab3){ref-type="table"}).

3.2. Promoter Methylation of*SFRP3*and Downregulation of *SFRP3* mRNA in HCC Cell Lines {#sec3.2}
---------------------------------------------------------------------------------------

We then investigated the methylation level of *SFRP3* promoter in four HCC cell lines (HA22T, HepG2, Hep3B, and TONG) using MSP and bisulfite sequencing. Among four HCC cell lines, our data demonstrated *SFRP3* was fully methylated in HA22T cells and partially methylated in the other cells ([Figure 2(a)](#fig2){ref-type="fig"}). Bisulfite sequencing results were summarized in [Figure 2(b)](#fig2){ref-type="fig"}. The CpGs in these regions was frequently methylated ([Figure 2(b)](#fig2){ref-type="fig"}). Quantitative RT-PCR data showed that downregulation of *SFRP3* mRNA in the four HCC lines with*SFRP3* hypermethylation ([Figure 2(c)](#fig2){ref-type="fig"}). To confirm that the lack of expression of *SFRP3*mRNA in the HCC lines was due to promoter hypermethylation, we treated cells with 5-aza-2′-deoxycytidine, an inhibitor of DNA methylation. After treatment with 5 µM of 5-aza-2′-deoxycytidine, the unmethylated promoter DNA was detected by MSP and bisulfite sequencing; *SFRP3* mRNA was restored or increased in the four HCC cell lines (Figures [2(a)](#fig2){ref-type="fig"}, [2(b)](#fig2){ref-type="fig"}, and [2(c)](#fig2){ref-type="fig"}). These data indicate that hypermethylation of *SFRP3* may be responsible for the absence or downregulation of mRNA transcription.

3.3. Downregulation of *SFRP3*mRNA Is Correlated with Promoter Methylation in Primary HCCs {#sec3.3}
------------------------------------------------------------------------------------------

To study the relation between *SFRP3* promoter methylation level and *SFRP3* mRNA expression, we first checked the mRNA level of 60 primary HCCs and their corresponding adjacent nontumor tissues by quantitative RT-PCR. Our data showed *SFRP3* mRNA expression was significantly downregulated in the primary HCCs as compared with the adjacent nontumor tissues (*P* \< 0.0001) ([Figure 3(a)](#fig3){ref-type="fig"}). Next, we checked the methylation status of the HCC cell lines and clinical HCC tissues by QMSP. Hypermethylation was confirmed in the HCC tissues compared with the nontumor liver tissues (*P* \< 0.01) ([Figure 3(b)](#fig3){ref-type="fig"}). In 36 of 60 HCCs (60%), *SFRP3* mRNA was significantly downregulated (by \>2-fold, [Table 4](#tab4){ref-type="table"}). There was a statistically significant association between the downregulation of *SFRP3* mRNA and the methylation status of *SFRP3*in HCCs (35/36 versus 17/24 resp.; *P* \< 0.01) ([Table 4](#tab4){ref-type="table"}). There were some HCCs without methylation; however, their *SFRP3*mRNA expression were downregulated.

4. Discussion {#sec4}
=============

Here we demonstrate that *SFRP3* is significantly hypermethylated and downregulated in HCCs when compared with control livers and nontumor livers (containing chronic hepatitis or cirrhosis livers) (*P* \< 0.0001, [Table 3](#tab3){ref-type="table"} and [Table 2](#tab2){ref-type="table"}). *SFRP3* mRNA expression could be restored or increased after HCC cells treatment with a DNA methyltransferase (DNMT) inhibitor, 5-aza-2′-deoxycytidine ([Figure 2](#fig2){ref-type="fig"}). We found a significant correlation between methylation and transcription level in primary tissues ([Table 4](#tab4){ref-type="table"}, *P* \< 0.001). In accordance with our data, promoter methylation has been detected in chronic hepatitis tissue and cirrhosis liver tissues, indicating that DNA methylation may be an early event in the pathogenesis of HCC \[[@B18], [@B40]\]. Put together, our data suggest that that downregulation of*SFRP3* mRNA through promoter hypermethylation is an early event during carcinogenesis and may be involved in the aberrant activation of Wnt/*β*-catenin signaling in HCC. Moreover, *SFRP3* mRNA was downregulated more than twofold in the absence of promoter hypermethylation in 71% of HCCs (17 of 24) ([Table 4](#tab4){ref-type="table"}). The decreased *SFRP3* mRNA level might be due to genetic changes or other epigenetic changes like histone modification.

Our data suggest that promoter hypermethylation of *SFRP3* is a common event in HCCs and plays an important role in regulation of *SFRP3* mRNA expression. Therefore epigenetic regulation of the Wnt/*β*-catenin pathway has been implicated as a possible therapeutic target in human cancer. Further investigations are required to explore the importance of *SFRP3* in the development of hepatocellular carcinoma.

5. Conclusions {#sec5}
==============

In conclusion, promoter hypermethylation of *SFRP3* is a frequent event in HCCs and epigenetic downregulation of *SFRP3* mRNA may contribute to aberrant activation of Wnt/*β*-catenin in HCC. This is the first report about hypermethylation and downregulation of *SFRP3* mRNA in HCC.
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![Methylation of *SFRP3* in primary hepatocellular carcinoma tissues. (a) Schematic representation of the promoter region and the first exon of the *SFRP3* gene. The CpG rich areas and the sites of methylation specific PCR (MSP), quantitative MSP, and bisulfite sequencing (BS) primers are indicated. (b) Representative results for four control livers (N1 to N5), four HCCs (T), and their corresponding nontumor livers (NT). Bisulfite-modified genomic DNA was amplified using methylation-specific or unmethylation-specific primer sets. M, methylation-specific PCR product; U, unmethylation-specific PCR. DNA from the peripheral blood lymphocyte (PBL) sample was used as a negative control, and PBL DNA treated with SssI Methylase (New England Biolabs, Beverly, MA) was a positive control. Case numbers are indicated at the top. (c) Summary of bisulfite sequencing. Case numbers of tumors, nontumor tissues, and normal control are indicated at the top. Black and white circles correspond to methylated or unmethylated, respectively.](DM2014-351863.001){#fig1}

![Promoter methylation and downregulation of*SFRP3* in HCC cell lines. (a) Detection of methylation in HCC cell lines using MS-PCR. M, methylation-specific PCR product; U, unmethylation-specific PCR. Four cell lines were treated for 4 days with the indicated concentration of 5-Aza-CdR. MS-PCR assay on DNA isolated from untreated or treated HCC cells. (b) Summary of bisulfite sequencing. The name of HCC cell line is indicated at the top. Black and white circles correspond to methylated or unmethylated, respectively. (c) HCC cell lines were treated with 5-aza-2′-deoxycytidine (5-Aza-CdR, DAC) for 4 days. The mRNA of *SFRP3* was analyzed by Q-RT-PCR. Expression of *GAPDH* was determined as a control for RNA quality. Significant differences were analyzed using the Mann-Whitney *U* test (\* for *P* \< 0.05 and \*\*\* for *P* \< 0.001).](DM2014-351863.002){#fig2}

![Frequent downregulation of *SFRP3* is associated with promoter hypermethylation in primary HCCs. The *SFRP3* transcripts of 60 primary HCCs (T) and their corresponding adjacent nontumor tissues (NT) were analyzed by RT-PCR and normalized to the internal control (*GAPDH*). Next, the methylation status of clinical HCC tissues was checked by QMSP and normalized to the internal reference gene *COL2A*. Significant differences were analyzed using the paired sample *t*-test or Mann-Whitney *U* test (\* for *P* \< 0.05 and \*\*\* for *P* \< 0.001).](DM2014-351863.003){#fig3}

###### 

The primer and probe sequences used in this study.

  Primer sequence (5′-3′)         Primer name   Assay
  ------------------------------- ------------- ----------------
  GTGTTGTTTTGGGGTTTTGTATTTGTATG   SFRP3 UF      MSPCR
  CTACCTCCCACCTAAAAAAAAACTCCAC    SFRP3 UR      MSPCR
  TTGGGGTGGGTTTTTTAGTGAGGGGT      BS01 F        BS sequencing
  AACAAAAAAAACRCTCAAAAAAAACC      BS01 R        BS sequencing
  GGCGTTGTTTTGGGGTTTCGTATTC       SFRP3 MF      MSPCR, QMSP
  TCCCGCCTAAAAAAAAACTCCG          SFRP3 MR      MSPCR, QMSP
  CTCTACCCTCCAATACC               probe         QMSP
  TCCCGAGGCCATCGTTACT             SFRP3 F       QRT-PCR (SyBr)
  AGGCTTACATTTACAGCGTTCAC         SFRP3 R       QRT-PCR

Sequence of *SFRP3* promoter:

aaaaaaaaagtccaagtgtattagagctgttagtttccacgttaacccttaaggagcaaagctcaagagttctaattccactaggtggggggggcgggaatagaaggaaaaaaccccttttccttgcttctggtggcctatttgtagtcat

gaacagcatttctttgtttctctctctctttttttttttttttaaaggcaatcctccccccacctcctcccccgcagttattgaaaatggagacctctgtagtcactagctctgggttgatatggctccaccgttgctcgcaggggtctgtgttttccg

ctacttggacaaagtgacattgcttaagcctttccccccaccaggtctgactttctgcagagccagtgattgcagaggaaaagctgtagtttgcttaaaggaaatacctccaggaaggagggtctcgggtgggttcccaagtggggaact

agggggacttttccgtagggaattggggtgggctcttcagtgaggggctaggggctcgtttctggggccaaagacgggttccctagtgtgagggcgcgctcgactcggcgctgtcttggggtctcgcactcgcacggcttcgcaccccac

cgcctgcgactcccaggccttctcttccccgggcgcccactccattctcgggaagagcagccggcactggagggcagagactgccccaggggcggagctccctctcaggcgggaggtaggaaagtgcagagccgcccgggcagagg

cacagacgtccctgcggggctcctcctgagcgtccctcctgccagccagggtcgcagccgcagcggcggccgcagctcttagcccacacaggacttgtaaactcttactgcacccttctctcccattaggagcttttcctccctccttccc

cccaacccctctgtcctcctcactttggggaatttaatgctttctttagcatctttttgtgtgcgtgatctaggggaggagacaccccagagctccaactagctctcagctgaattctacttttgtttttatgtcttcctcgcctcctctcgtgtcc

ctcttatctgactgatctgcgaagtctgatgcttctgccagagggagaggaataaatagatgttgctgcttccgaaggcttagacGTTGGGAAAGAGCAGCCTGGGCGGCAGGGGCGGTGGCTG

GAGCTCGGTAAAGCTCGTGGGACCCCATTGGGGGAATTTGATCCAAGGAAGCGGTGATTGCCGGGGGAGGAGAAGCTCCCAGATCCTTGTG

TCCACTTGCAGCGGGGGAGGCGGAGACGGCGGAGCGGGCCTTTTGGCGTCCACTGCGCGGCTGCACCCTGCCCCATCCTGCCGGGATC.

###### 

*SFRP3* mRNA expression in primary HCCs by relative quantitative RT-PCR.

  -------------------------------------------------------------------------
  Patient no.   *SFRP3* methylation   ΔCt      ΔΔCt    *SFRP3* tumor part
  ------------- --------------------- -------- ------- --------------------
  1T            U                     9.03     1.68    0.3121

  1NT           U                     7.35             

                                                       

  2T            M                     10.05    2.81    0.1426

  2NT           M                     7.24             

                                                       

  3T            U                     7.63     −0.47   1.3851

  3NT           U                     8.10             

                                                       

  4T            U                     7.58     −0.51   1.4191

  4NT           U                     8.09             

                                                       

  5T            U                     11.54    0.82    0.5684

  5NT           U                     10.72            

                                                       

  6T            U                     5.92     −0.29   1.2226

  6NT           U                     6.21             

                                                       

  7T            M                     7.40     1.38    0.3856

  7NT           U                     6.03             

                                                       

  8T            U                     15.00    6.10    0.0146

  8NT           U                     8.91             

                                                       

  9T            M                     8.95     1.91    0.2661

  9NT           U                     7.04             

                                                       

  10T           M                     9.03     1.79    0.2892

  10NT          M                     7.24             

                                                       

  11T           M                     15.00    9.03    0.0019

  11NT          M                     5.97             

                                                       

  12T           M                     9.10     1.35    0.3923

  12NT          M                     7.75             

                                                       

  13T           U                     9.62     1.58    0.3356

  13NT          U                     8.04             

                                                       

  14T           U                     6.27     −0.71   1.6358

  14NT          U                     6.98             

                                                       

  15T           M                     15.00    7.90    0.0042

  15NT          U                     7.10             

                                                       

  16T           M                     15.00    7.14    0.0071

  16NT          M                     7.86             

                                                       

  17T           M                     9.34     1.13    0.4569

  17NT          M                     8.21             

                                                       

  18T           U                     5.10     −1.01   2.0069

  18NT          U                     6.11             

                                                       

  19T           M                     6.75     1.04    0.4863

  19NT          M                     5.71             

                                                       

  20T           U                     15.00    7.87    0.0043

  20NT          U                     7.14             

                                                       

  21T           M                     15.00    8.13    0.0036

  21NT          U                     6.87             

                                                       

  22T           U                     9.92     3.48    0.0899

  22NT          U                     6.45             

                                                       

  23T\          M\                    9.05\    1.42    0.3737
  23NT          M                     7.63             

                                                       

  24T           M                     8.47     1.24    0.4248

  24NT          M                     7.23             

                                                       

  25T           M                     6.96     0.61    0.6552

  25NT          M                     6.35             

                                                       

  26T           U                     5.14     0.11    0.9298

  26NT          U                     5.04             

                                                       

  27T           M                     12.37    5.31    0.0253

  27NT          M                     7.06             

                                                       

  28T           M                     15.00    6.21    0.0136

  28NT          U                     8.80             

                                                       

  29T           U                     5.67     2.49    0.1780

  29NT          U                     3.18             

                                                       

  30T           M                     9.23     1.44    0.3680

  30NT          U                     7.79             

                                                       

  31T           U                     15.00    6.34    0.0123

  31NT          U                     8.66             

                                                       

  32T           U                     8.28     1.18    0.4429

  32NT          U                     7.11             

                                                       

  33T           U                     12.14    5.96    0.0161

  33NT          U                     6.18             

                                                       

  34T           U                     7.63     2.47    0.1811

  34NT          U                     5.16             

                                                       

  35T           M                     6.98     4.65    0.0398

  35NT          M                     2.33             

                                                       

  36T           M                     15.00    5.01    0.0310

  36NT          M                     9.99             

                                                       

  37T           U                     15.00    9.40    0.0015

  37NT          U                     5.61             

                                                       

  38T           M                     15.00    10.72   0.0006

  38NT          M                     4.28             

                                                       

  39T           M                     7.90     1.10    0.4665

  39NT          U                     6.80             

                                                       

  40T           M                     15.00    7.48    0.0056

  40NT          U                     7.52             

                                                       

  41T           M                     8.97     1.22    0.4308

  41NT          U                     7.75             

                                                       

  42T           M                     9.25     2.17    0.2222

  42NT          U                     7.08             

                                                       

  43T           U                     15.00    8.77    0.0023

  43NT          U                     6.23             

                                                       

  44T           M                     8.76     0.22    0.8586

  44NT          M                     8.54             

                                                       

  45T           M                     8.92     2.86    0.1377

  45NT          U                     6.06             

                                                       

  46T\          U\                    10.34\   2.17    0.2222
  46NT          U                     8.17             

                                                       

  47T           M                     15.00    9.13    0.0018

  47NT          U                     5.88             

                                                       

  48T           U                     15.00    9.16    0.0018

  48NT          U                     5.85             

                                                       

  49T           M                     15.00    9.43    0.0014

  49NT          U                     5.57             

                                                       

  50T           M                     15.00    6.78    0.0091

  50NT          U                     8.22             

                                                       

  51T           M                     15.00    6.16    0.0140

  51NT          U                     8.85             

                                                       

  52T           M                     15.00    10.77   0.0006

  52NT          U                     4.24             

                                                       

  53T           U                     11.21    3.77    0.0733

  53NT          U                     7.44             

                                                       

  54T           M                     12.27    10.28   0.0008

  54NT          U                     1.99             

                                                       

  55T           M                     15.00    4.94    0.0326

  55NT          U                     10.06            

                                                       

  56T           U                     7.74     1.98    0.2535

  56NT          U                     5.76             

                                                       

  57T           U                     10.39    3.52    0.0872

  57NT          U                     6.87             

                                                       

  58T           M                     15.00    9.01    0.0019

  58NT          U                     5.99             

                                                       

  59T           M                     11.36    3.99    0.0632

  59NT          U                     7.38             

                                                       

  60T           M                     7.52     2.55    0.1713

  60NT          U                     4.97             
  -------------------------------------------------------------------------

NT: nontumor part; T: tumor part; M: methylated; U: unmethylated.

The range given for *SFRP3* tumor part relative to nontumor part is determined by evaluating the expression: 2^−ΔΔCt^.

###### 

Frequency of *SFRP3* promoter methylation in 30 control livers and 60 paired HCC and adjacent nontumor tissue samples.

  Diagnosis                      No. of cases with *SFRP3* methylation   *P* value
  ------------------------------ --------------------------------------- -----------
  Control livers\* (*n* = 30)    0 (0%)                                  \<0.0001
  Chronic hepatitis (*n* = 37)   6 (16.2%)                               
  Cirrhosis (*n* = 23)           9 (39.1%)                               
  HCC (*n* = 60)                 36 (60%)                                

\*Thirty control tissues were from 30 hepatic hemangiomas. Statistical analysis was determined by chi-square test.

###### 

Statistical correlation between *SFRP3* mRNA expression and methylation status of *SFRP3* CpG island in HCCs.

  ----------------------------------------------------------------------------------------------------------------
                                        Methylation of CpG island\   No methylation of CpG island\   *P* value
                                        (no. of cases)               (no. of cases)                  
  ------------------------------------- ---------------------------- ------------------------------- -------------
  Downregulation of *SFRP3* ≥ twofold                                                                 

   Present                              35                           17                              *P* \< 0.01

   Absent                               1                            7                               
  ----------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Valeria Barresi
